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A fehérállományi laesiók a sclerosis multiplex (SM)
meghatározó jellemzôi, a szürkeállomány elváltozásai
kevésbé ismertek.  A megfelelô agyi képalkotó eljárásokkal
végzett újabb vizsgálatokban láthatóvá tudták tenni a kérgi
elváltozásokat. Emellett különféle módszerekkel felmérhetô a
szürkeállományi atrophia. Számos vizsgálat eredményei
szerint a szürkeállomány atrophiája szorosan korrelál a
klinikai rokkantsággal. Összefoglaljuk az SM-ben megfigyel-
hetô szürkeállományi atrophiával kapcsolatos információkat
és a betegségmódosító terápiák hatását az agyi atrophiára.
Kulcsszavak: sclerosis multiplex, atrophia, szürkeállomány,
MRI, voxelalapú morfometria
White matter lesions are defining characteristics of multiple
sclerosis (MS), whereas grey matter involvement is a less
recognised attribute. Recent investigations using dedicated
imaging approaches have made it possible to depict cortical
lesions. Additionally, grey matter atrophy may be estimated
using various methods. Several studies have suggested that
grey matter atrophy closely correlates to clinical disability. In
this review we have collected information on grey matter
atrophy in MS and the effect of disease modifying therapies
upon brain atrophy. 
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Multiple sclerosis (MS) is an inflammatory,neurodegenerative disease. The primary fea-
ture of MS is the demyelination paralleled by vary-
ing degrees of axonal damage1. The focal inflam-
matory demyelinating lesions in the white matter
are not only the hallmarks of the disease, but in vivo
demonstration of these lesions with MR imaging is
also part of the diagnosis2. Recently, it has become
clear that grey matter is also adversely affected.
This review aims to summarize the recent advances
made by studies assessing grey matter atrophy in
MS patients for both clinical and scientific purpos-
es. 
Grey matter lesions
Early post-mortem histological studies established
the existence of grey matter lesions in MS
patients3–6. Grey matter lesions are classified as
Types I to IV. Type I lesions, located at the border
of the grey and white matter, rarely occur. Type II
lesions occur within the cortex. Type III subpial
lesions are the most frequent. Type IV lesions cover
the full width of the cortex and occur infrequently.
While the neuropathological studies4–9 have provid-
ed insight into the cortical pathology, these studies
are limited by the inclusion of patients with differ-
ent disease types and stages, consequently restrict-
ing inter-study comparability. Advanced MRI
methods may offer an alternative approach to track
progression of the grey matter lesions and elucidate
their significance in the disease process. With mod-
ern MRI sequences, such as the double inversion
recovery10, 11 it is possible to detect many more cor-
tical lesions than conventional T2 weighted
sequences. However, the detection rate is still only
around 20% when compared to neuropathological
investigations12. Furthermore, the inter-rater agree-
ment in identifying lesions is rather low13. Ultra-
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high field imaging may facilitate increased sensi-
tivity and specificity of the grey matter lesion detec-
tion13, although the modality is not widely available. 
Grey matter atrophy
Apart from depicting grey matter lesions MRI
investigations are also capable of identifying grey
matter atrophy. There are several approaches avail-
able to evaluate grey matter atrophy. Apart from
manual segmentation, gross grey matter volume can
be estimated (cortical with or without subcortical)
by automatic segmentation of brain tissue types14–16.
Another approach for detecting atrophy is by meas-
uring cortical thickness. One of the most common
approaches for this is the voxel-wise comparison of
intensities (or more precisely the probability of tis-
sue types in individual voxels)15, 17. The advantage
of this method is that it can identify focal atrophy.
However, inter-subject registration is the critical
limitation of this method. 
MRI studies employing various methodologies
agree on the significant grey matter atrophy in MS.
The earliest MRI study on gross brain atrophy using
manual measurements showed significant brain vol-
ume change in MS patients18, as confirmed by semi-
automatic larger dataset studies19–22. Likewise, the
brain parenchymal fraction (the ratio of the premor-
bid brain size -measured as intracranial volume- and
the brain parenchymal volume) is about 3-5% small-
er compared to normal controls23–25 and considerably
smaller in secondary progressive MS26. Tissue type
segmentation made it possible to identify atrophy in
both grey24, 26–28 and white matter26, 29.
Voxel-based morphometry (VBM) studies
demonstrated that the grey matter atrophy is not uni-
form over the cortex (Table 1.). These studies
revealed that the grey matter pathology exhibits con-
siderable heterogeneity in patients, because a clear
pattern of grey matter atrophy cannot always be
established. Other studies failed to find atrophy in
MS patients when compared to controls subjects.
Audoin and co-workers found no difference between
control subjects and relapsing-remitting MS patients
early in their disease course. However over two
years, atrophy developed in the bilateral thalami and
the right frontal cortex30. Similarly Sepulcre et al.
found no focal grey matter atrophy in 31 primary pro-
gressive MS (PPMS) subjects, except in the cerebel-
lum when not correcting for multiple comparisons31.
Nevertheless, if a specific pattern of grey matter atro-
phy is to be tentatively established, than the thalamus
is invariably affected, as well as the temporal, insular
and frontal lobes (often sensory-motor cortex). 
The location of white matter lesions in MS or the
total lesion load only moderately correlate with clin-
ical symptoms and cognitive impairment (clinic-radi-
ological paradox32). Several reports suggested that
disability has a closer relationship with grey matter
atrophy33. However, upon closer inspection of these
studies, using VBM approach correlation between
focal atrophy and disability was identified infre-
quently. Audoin found correlation between expand-
ed disability status scale (EDSS34) and focal atrophy
in the cerebellum35. With regard to the cognitive per-
formance, Morgen and co-workers found extensive
correlation with paced auditory serial addition test
(PASAT) scores36. Cerasa and colleagues, using
many cognitive tests, only found correlation with
performance on symbol digit modalities (SDM) and
controlled oral word association test (COWAT)37. 
Moreover, global grey matter atrophy was found
to correlate with the clinical features of the disease
as measured via the EDSS19, 25, 26, 38, 39 and cognitive
function tests39–42.
Pathology and pathophysiology of grey
matter injury in multiple sclerosis
The methods for detecting grey matter pathology are
especially important, considering the grey matter
demyelination in MS. Gilmore et al. reported an
“overall 28.8% of the grey matter demyelinated as
compared with only 15.6% of the white matter”7.
Most of this demyelination (about 60%) is subpial6
and is present in the form of ribbon like demyelina-
tion often affecting several adjacent gyri. Impor -
tantly, based on post-mortem MRI imaging of three
MS cases there was no association between the corti-
cal demyelination and the focal or diffuse white mat-
ter pathology43. The various mechanisms behind the
lesions are indicated by the fact that in contradistinc-
tion to the white matter lesions, in cortical lesions
there is no inflammatory cell infiltration and foamy
macrophages, immunoglobulin deposition or com-
plement activation is scarce44, 45. Meninges were also
shown to be affected in MS46, 47, B-cell follicle-like
structures were described in the inflamed meninges.
More recently this meningeal inflammation was
hypothesized to be the major contributor to the corti-
cal pathology: the B-cell follicle-like structures were
associated with increased subpial demyelination and
cortical atrophy48. Apart from the demyelination, a
gradient of neuronal loss was observed in the affect-
ed cortex, which was accompanied by astrocyte loss
and opposite to this gradient a microglia activation48.
These changes were suggested to be consistent with
a non-targeted general immunopathological response
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mediated by the CD8+ T cells via cytotoxic tissue
damage or indirectly through the activation of
microglia. Furthermore, neuronal loss was found in
layers III and V in regions where no B-cell follicle-
like structures were detected, this suggests that other
mechanisms are also involved in the atrophy.
Neurodegeneration due to inflammatory insults in
downstream white matter tracts, reduced synaptic
and glial density may also contribute to the atrophy49,
50. 
Various mechanisms were proposed behind the
neurodegeneration in MS. Neuroinflammation can
directly induce apoptosis through various cytokines
and the oxidative burst arising from the activated
microglias may also contribute51. As in many neu-
rodegenerative diseases52, oxidative stress and
mitochondrial dysfunction are proposed to be a
major mediators of neurodegeneration and axonal
loss in MS53–55. Another key component in MS neu-
rodegeneration is glutamate excitotoxicity56 and
recently a link between inflammation and excito-
toxicity was established57. Furthermore, a possible
mechanism of neurodegeneration might be an
imbalance of neuroprotective and neurotoxic
agents, such as the metabolites of the kynurenine
pathway a major biochemical pathway in trypto-
phan metabolism58–60.
Grey matter atrophy as a biomarker
for therapeutic efficacy
It is becoming progressively more evident that grey
matter atrophy is a stronger predictor of disability
progression in MS than white matter pathology.
Moreover, it may also be used as a complementary
MRI method for disease progression instead of con-
ventional MRI techniques25, 39, 61–63. Thus, making it
a promising biomarker for therapeutic response in
pharmacological studies. 
INTRAMUSCULAR INTERFERON β-1A
A post hoc analysis of the MRI images from 140
patients (72 in the placebo arm, 68 in the treatment
arm) participating in a phase III clinical trial of
intramuscular interferonβ-1a (INFβ-1a, Avonex)
showed a reduced rate of the atrophy (brain
parenchymal fraction) in the treatment arm64. While
there was no difference between the two treatment
groups in the first year of treatment, during the sec-
ond year INFβ-1a reduced the rate of atrophy by
55%. In a subsequent study, treatment over two
years with intramuscular, subcutaneous INFβ-1a
and glatiramer acetate (GA) resulted in a decreased
rate of reduction in brain gray matter fraction65. A
three-year period open-label study using intramus-
cular INFβ-1a found a reduced whole-brain and
GM atrophy, as well as of T1-hypointense lesion
volume accumulation in the treatment group66.
When compared to year one weekly intramuscular
INFβ-1a treatment data, the atrophy rate was
reduced in the second and third year of treatment74.
Subsequent analysis of a 138 patients subgroup
having frequent MRI scans, showed that the major-
ity of the atrophy during the first year (approximate-
ly 70%) occurred during the first four months74. 
INTERFERON β-1B
Five years post INFβ-1b clinical trials for patients
with PPMS, not only were motor and cognitive per-
formance better, but also the decrease of brain
parenchymal fraction was similarly smaller75. In an
earlier randomized study, which measured the
parenchymal volumes only in the central slab failed
to demonstrate a beneficial effect of INFβ-1b76. A
smaller open-label study with RRMS patients also
failed to demonstrate completely the beneficial
effect of INFβ-1b, a reduced rate of atrophy was
observed only in the second year, but not in the first
or third years of treatment77. 
SUBCUTANEOUS INTERFERON β-1A
In the PRISM trial neither high dose nor low dose
(22 and 44 µg three times weekly) INFβ-1a–Rebif
showed a beneficial effect against reduction of the
whole brain volume78. In contrast, in the ETOMS
study, subcutaneous INFβ-1a (once weekly 22 µg)
given to patients after the first attack, not only
delayed the appearance of a second relapse but also
reduced the rate of atrophy over two years as meas-
ured with SIENA67. Furthermore, in a comparative
study, glatiramer acetate, intramuscular and subcu-
taneous INFβ-1a was superior to placebo in reduc-
ing brain atrophy at 24 months, while no difference
between treatment outcomes was detected65. In
Gasperini’s study there was no difference in brain
atrophy using 11µg and 33 µg subcutaneous INFβ-
1b treatment (three times weekly)79. 
GLATIRAMER ACETATE
In the open-label extension of the US GA trial, the
patients who were in the placebo arm originally had
more brain volume loss as compared to subjects
receiving glatiramer acetate (GA) treatment80. Kahn
and co-workers showed a significantly reduced loss
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of brain volume in patients receiving disease-modi-
fying therapy81 and having only minor progression
in their disability (EDSS). Ge and colleagues found
reduced rates of brain tissue loss over 24 months of
GA treatment in comparison to placebo treated sub-
jects70. Conversely, a nine months placebo con-
trolled study showed no significant benefit of GA
on brain atrophy68. Importantly, in a comparative
study GA reduced the rate of atrophy more than low
and high doses of INFβ-1a81, while low dose INFβ-
1a was more effective than high dose81. However,
Calabrese found the use of GA, intramuscular
INFβ-1a or subcutaneous INFβ-1a similarly effec-
tive in reducing grey matter atrophy65. 
NATALIZUMAB
While natalizumab is effective in reducing MRI-
measured disease activity (T2 lesion load and
enhancing lesions) the results on brain atrophy are
controversial71. In the first year of natalizumab
treatment a pseudoatrophy appears, which over the
next two years converts to a significant reduction of
brain volume reduction71, 82. This phenomenon was
related to the cessation of inflammatory activity.  
In comparative studies natalizumab was more
effective in reducing grey matter atrophy. The
analysis of the secondary and the tertiary MRI
measures in the SENTINEL study showed that
among beneficial effect of combined intramuscular
INFβ-1a and natalizumab (T2 lesion volume, T1
hypointense lesions, enhancing lesions) treatment
the atrophy rate was reduced when compared to the
group receiving INFβ-1a alone83. In RRMS patients
enrolled in a non-randomised pilot study, signifi-
cantly lower changes in brain parenchymal volume
were recorded in those treated with natazilumab
(n=12) in comparison to those receiving INFβ
(n=14)84.  In a two-year-prospective study nata -
zilumab was also superior to the immunmodulatory
agents GA and INFβ in reducing the accumulation
of cortical lesions as well as cortical atrophy85. 
FINGOMILOD
Fingolimod is a sphingosine-1-phosphate-receptor
modulator that prevents lymphocyte egress from
lymph nodes: it has shown clinical efficacy in phase
II86 and III clinical trials72. The efficacy of the drug
was also proved with paraclinical measures. New
T2 lesions as well as the number of gadolinium
enhancing lesions were reduced in the group receiv-
ing fingolimod when compared to patients receiv-
ing intramuscular INFβ72, 86. While in a six-month
phase II study, there was no improvement in the rate
of brain atrophy as compared to placebo arm86.
However, the 12 months phase III study (TRANS-
FORMS) revealed significant improvement in the
brain atrophy rate in comparison to intramuscular
INFβ treatment72, this effect was evident in the sub-
group analysis also87. Phase III (FREEDOMS)
study showed significant reduction of brain atrophy
rate in fingolimod treated patients at 6, 12 and 24
months73. Interestingly, this effect was unrelated to
the T2 lesion load or the number of enhancing
lesions (Table 2.)88. 
Conclusions
Paraclinical examinations in the diagnosis of MS
such as MRI have a central role. However it is
important that conventional MRI modalities cannot
identify the full range of abnormalities. Sophis -
ticated analysis approaches have to complement the
expert eye of physician and advanced neuroimag-
ing have to complement traditional neuroradiology
in order to further elucidate the disease pathomech-
anism and tailor treatment efficacy. 
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Table 2. The effect of treatment on grey matter atrophy
First year Second year First two years
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GA 68, 69 ††68, 69 65, 70
Natalizumab 71† 71 71
Fingolimod 72, 73†††† 73 73
†pseudoatrophy, †18 months, †††three years, ††††at six months also
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